S.L. MOROZOV^{1, 2}, V.P. PAKHOMOVA¹, V.YU. VOINOVA^{1, 2}

 ¹Veltischev Research and Clinical Institute for Pediatrics, Moscow

²Pirogov Russian National Research Medical University, Moscow

 Contact details:

Morozov S.L. — Ph. D. (Medicine), Leading Researcher of the Department of Hereditary and Acquired Diseases of Kidneys named after Prof. M.S. Ignatova, Associate Professor of the Department of Hospital Pediatrics No. 2 of Pediatric Faculty

Address: 2 Taldomskaya St., Moscow, Russian Federation, 125412, tel.: +7-903- 138-77-32, e-mail: mser@list.ru

 Worldwide, nephrotic syndrome in children is the most common glomerulopathy. One of the pressing issues in pediatric nephrology is the formation of dependence or resistance to steroid drugs in the treatment of nephrotic syndrome, which has made it possible to develop the field of pharmacotranscriptomics. Understanding the quantitative contribution of genetic factors to phenotype is an important aspect of developing personalized treatment strategies. In addition to molecular genetic analysis of polymorphisms affecting the primary structure of proteins, it is proposed to systematically use expression in order to quantify the role of these factors in transcription and processing of mRNA. This article discusses the results of a study of the express genes MDR1 and NR3C1, which are associated with steroid dependence in children with idiopathic nephrotic syndrome.

Key words: Children, nephrotic syndrome, transcription, RNA, MDR1, NR3C1.

REFERENCES

1. El Bakkali L., Rodrigues Pereira R., Kuik D.J., Ket J.C.F., Van Wijk J.A.E. Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature. Pediatric Nephrology, 2011, vol. 26, Nephrotic syndrome in The Netherlands, no. 8, pp. 1241–1246.
2. Schijvens A.M., Ter Heine R., De Wildt S.N., Schreuder M.F. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatric Nephrology, 2019, vol. 34 (3), pp. 389–403.
3. Tarshish P., Tobin J.N., Bernstein J., Edelmann C.M. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J. Am. Soc. Nephrol, 1997, vol. 8, Prognostic significance of the early course of minimal change nephrotic syndrome, no. 5, pp. 769–776.
4. Morozov S.L., Aksenova M.E. Primary nephrotic syndrome in children. Prospects for personalized therapy. Prakticheskaya meditsina, 2018, vol. 8, pp. 39–42 (in Russ.).
5. Morozov S.L., Dlin V.V. On the issue of steroid therapy for primary nephrotic syndrome in children. Prakticheskaya meditsina, 2020, vol. 18, no. 3, pp. 26–31 (in Russ.).
6. Morozov S.L., Dlin V.V., Sadykov A.R., Voronkova A.S., Sukhorukov V.S. Mechanisms of resistance to immunosuppressive therapy in patients with nephrotic syndrome. Rossiyskiy vestnik perinatologii i pediatrii, 2017, vol. 62, no. 4, pp. 19–24 (in Russ.).
7. Rovin B.H., Adler S.G., Barratt J., Bridoux F., Burdge K.A. et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, vol. 100 (4), pp. 753–779.
8. Samuel S.M., Flynn R., Zappitelli M., Dart A., Parekh R., Pinsk M. et al. For the Canadian Childhood Nephrotic Syndrome Project Team* Factors influencing practice variation in the management of nephrotic syndrome: a qualitative study of pediatric nephrology care providers. CMAJ Open, 2017, vol. 5, Factors influencing practice variation in the management of nephrotic syndrome, no. 2, pp. E424–E430.
9. Czock D., Keller F., Rasche F.M., Hussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clinical Pharmacokinetics, 2005, vol. 44; Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids, no. 1, pp. 61–98.
10. Evans W.E. Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut, 2003, vol. 52; Pharmacogenomics, no. 90002, p. 10ii-1018.
11. Andrews L.M., Li Y., De Winter B.C.M., Shi Y.-Y., Baan C.C., Van Gelder T., Hesselink D.A. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opinion on Drug Metabolism & Toxicology, 2017, vol. 13 (12), pp. 1225–1236.
12. Chiou Y.-H., Wang L.-Y., Wang T.-H., Huang S. Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatric Nephrology, 2012, vol. 27 (9), pp. 1511–1517.
13. Youssef D.M., Attia T.A., El-Shal A.S., Abduelometty F.A. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: Impact on susceptibility and response to steroids. Gene, 2013, vol. 530; Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome, no. 2, pp. 201–207.
14. Moussa A., Mabrouk S., Hamdouni H., Ajmi M., Tfifha M., Omezzine A. et al. MDR-1 and CYP3A5 polymorphisms in pediatric idiopathic nephrotic syndrome: impact on susceptibility and response to steroids (preliminary results). Clinical Laboratory, 2017, vol. 63; MDR-1 and CYP3A5 Polymorphisms in Pediatric Idiopathic Nephrotic Syndrome, No. 07+08/2017.
15. Youssef D.M., Elbehidy R.M., Abdelhalim H.S., Amr G.E. Soluble interleukine-2 receptor and MDR1 gene expression levels as inflammatory biomarkers for prediction of steroid response in children with nephrotic syndrome. Iranian Journal of Kidney Diseases, 2011, vol. 5 (3), pp. 154–161.
16. Prasad N., Singh H., Jaiswal A., Chaturvedi S., Agarwal V. Overexpression of P-glycoprotein and MRP-1 are pharmacogenomic biomarkers to determine steroid resistant phenotype in childhood idiopathic nephrotic syndrome. The Pharmacogenomics Journal, 2021,v. 21 (5), pp. 566–573.
17. Hirano T., Onda K., Toma T., Miyaoka M., Moriyasu F., Oka K. MDR1 mRNA Expressions in Peripheral Blood Mononuclear Cells of Patients with Ulcerative Colitis in Relation to Glucocorticoid Administration. J. Clin. Pharmacol, 2004, vol. 44 (5), pp. 481–486.
18. Hlavaty J., Ertl R., Mekuria T.A., Rütgen B., Tsujimoto H., Walter I., Wolfesberger B. Effect of prednisolone pre-treatment on cat lymphoma cell sensitivity towards chemotherapeutic drugs. Research in Veterinary Science, 2021, vol. 138, pp. 178–187.
19. Banaszak B., Banaszak P. The increasing incidence of initial steroid resistance in childhood nephrotic syndrome. Pediatric Nephrology, 2012, vol. 27 (6), pp. 927–932.
20. Hodson E., Knight J., Willis N., Craig J. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2005. P. CD001533.pub3.
21. Brambila-Tapia A.J.-L. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, 2013, vol. 65; MDR1 (ABCB1) polymorphisms, no. 5, pp. 445–454.
22. Gamal Y., Badawy A., Swelam S., Tawfeek M.S.K., Gad E.F. Glomerular glucocorticoid receptors expression and clinicopathological types of childhood nephrotic syndrome. Fetal and Pediatric Pathology, 2017, vol. 36 (1), pp. 16–26.
23. Pakhomova V.P. Farmakogeneticheskie markery effektivnosti immunosupressivnoy terapii pervichnogo nefroticheskogo sindroma u detey. Diplomnaya rabota [Pharmacogenetic markers of the effectiveness of immunosuppressive therapy for primary nephrotic syndrome in children. Graduate work], 2024. 53 p.
24. Turner J.D., Schote A.B., Macedo J.A., Pelascini L.P.L., Muller C.P. Tissue specific glucocorticoid receptor expression, a role for alternative first exon usage? Biochemical Pharmacology, 2006, vol. 72 (11), pp. 1529–1537.
25. Wasilewska A., Zoch-Zwierz W., Tomaszewska B., Wiercinski R., Stasiak-Barmuta A. Expression of glucocorticoid receptors in mononuclear cells in nephrotic syndrome. Pediatric Nephrology, 2003, vol. 18 (8), pp. 778–782.
26. Sher E.R., Leung D.Y., Surs W., Kam J.C., Zieg G., et al. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J. Clin. Inv, 1994, vol. 93 (1), pp. 33–39.
27. Hejazian S.M., Zununi Vahed S., Moghaddas Sani H., Nariman-Saleh-Fam Z. et al. Steroid-resistant nephrotic syndrome: pharmacogenetics and epigenetic points and views. Expert Review of Clinical Pharmacology, 2020, vol. 13; Steroid-resistant nephrotic syndrome, no. 2, pp. 147–156.